{
  "claim_id": "claim_002",
  "claim": "Cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
  "document": "Arunachalam_et_al.__2021_",
  "verified_evidence": [
    {
      "id": 1,
      "quote": "POTENTIAL ANTIGENIC MISMATCH OF INFLUENZA VACCINE VIRUS GROWN IN EGG OR CELLS DUE TO ADAPTIVE MUTATIONS IN THE HA PRIMARY STRUCTURE A known risk of traditional split or subunit vaccines is the potential for the candidate vaccine virus or working virus seeds to acquire adaptive mutations as they grow in embryonated chicken egg or mammalian host cells during vaccine manufacture. Such adaptive mutations in HA peptides may reduce the effectiveness of the resultant vaccine 24 26.",
      "supports_claim": true,
      "explanation": "The quote appears on page 2 of the document, with only minor formatting differences. The factual content is preserved: 'POTENTIAL ANTIGENIC MISMATCH OF INFLUENZA VACCINE VIRUS GROWN IN EGG OR CELLS DUE TO ADAPTIVE MUTATIONS IN THE HA PRIMARY STRUCTURE A known risk of traditional split or subunit vaccines is the potential for the candidate vaccine virus or working virus seeds to acquire adaptive mutations as they grow in embryonated chicken egg or mammalian host cells during vaccine manufacture. Such adaptive mutations in HA peptides may reduce the effectiveness of the resultant vaccine 24 26.' This matches the quote to verify in all substantive details.. The quote directly supports the claim. It explicitly states that traditional split or subunit influenza vaccines, which are produced in eggs or mammalian cells, have the potential to acquire adaptive mutations during production. It further states that such mutations in the HA (hemagglutinin) peptides may reduce the effectiveness of the resultant vaccine. This is a direct and explicit confirmation of the claim that cell- and egg-based flu vaccines can develop mutations during production that may reduce their effectiveness.",
      "presence_explanation": "The quote appears on page 2 of the document, with only minor formatting differences. The factual content is preserved: 'POTENTIAL ANTIGENIC MISMATCH OF INFLUENZA VACCINE VIRUS GROWN IN EGG OR CELLS DUE TO ADAPTIVE MUTATIONS IN THE HA PRIMARY STRUCTURE A known risk of traditional split or subunit vaccines is the potential for the candidate vaccine virus or working virus seeds to acquire adaptive mutations as they grow in embryonated chicken egg or mammalian host cells during vaccine manufacture. Such adaptive mutations in HA peptides may reduce the effectiveness of the resultant vaccine 24 26.' This matches the quote to verify in all substantive details.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that traditional split or subunit influenza vaccines, which are produced in eggs or mammalian cells, have the potential to acquire adaptive mutations during production. It further states that such mutations in the HA (hemagglutinin) peptides may reduce the effectiveness of the resultant vaccine. This is a direct and explicit confirmation of the claim that cell- and egg-based flu vaccines can develop mutations during production that may reduce their effectiveness.",
      "original_relevance": "This quote explicitly states that cell- and egg-based flu vaccines can acquire adaptive mutations during production, and that these mutations may reduce vaccine effectiveness, directly supporting the claim."
    },
    {
      "id": 2,
      "quote": "Raymond et al.24 showed that an egg adapted A/California/07/2009 (H1 N1) vaccine strain acquired a mutation resulting in the substitution of glutamine with arginine at position 226 which in turn induced antibodies specific to receptor binding site that bound to vaccine derived HA preferentially over the circulating wild type virus 24.",
      "supports_claim": true,
      "explanation": "The quote appears on page 2 of the document, in the section titled 'POTENTIAL ANTIGENIC MISMATCH OF INFLUENZA VACCINE VIRUS GROWN IN EGG OR CELLS DUE TO ADAPTIVE MUTATIONS IN THE HA PRIMARY STRUCTURE.' The text states: 'Raymond et al.24 showed that an egg adapted A/California/07/2009 (H1 N1) vaccine strain acquired a mutation resulting in the substitution of glut amine with arginine at position 226 which in turn induced antibodies specific to receptor binding site that bound to vaccine derived HA preferentially over the circulating wild type virus 24.' This matches the quote to verify, with only minor formatting differences (e.g., 'glut amine' vs 'glutamine'). All technical content and facts are preserved.. The quote directly supports the claim. It provides a concrete example of a mutation (glutamine to arginine at position 226) arising during egg-based vaccine production, and explains that this mutation altered the immune response such that antibodies preferentially bound to the vaccine-derived HA rather than the circulating wild type virus. This demonstrates that mutations can occur during production and may reduce vaccine effectiveness, as the claim asserts.",
      "presence_explanation": "The quote appears on page 2 of the document, in the section titled 'POTENTIAL ANTIGENIC MISMATCH OF INFLUENZA VACCINE VIRUS GROWN IN EGG OR CELLS DUE TO ADAPTIVE MUTATIONS IN THE HA PRIMARY STRUCTURE.' The text states: 'Raymond et al.24 showed that an egg adapted A/California/07/2009 (H1 N1) vaccine strain acquired a mutation resulting in the substitution of glut amine with arginine at position 226 which in turn induced antibodies specific to receptor binding site that bound to vaccine derived HA preferentially over the circulating wild type virus 24.' This matches the quote to verify, with only minor formatting differences (e.g., 'glut amine' vs 'glutamine'). All technical content and facts are preserved.",
      "support_explanation": "The quote directly supports the claim. It provides a concrete example of a mutation (glutamine to arginine at position 226) arising during egg-based vaccine production, and explains that this mutation altered the immune response such that antibodies preferentially bound to the vaccine-derived HA rather than the circulating wild type virus. This demonstrates that mutations can occur during production and may reduce vaccine effectiveness, as the claim asserts.",
      "original_relevance": "This quote provides a concrete example of a mutation arising during egg-based vaccine production that altered the immune response, supporting the claim that such mutations can occur and affect effectiveness."
    },
    {
      "id": 3,
      "quote": "During the 2012-2013 northern hemisphere influenza vaccination campaign, HA from an egg adapted A/Victoria/361/2011 (H3 N2) virus used for vaccine manufacturing differed from the WHO-recommended prototype and several other wild type influenza viruses in three positions, H156Q, G186V, and S219Y25. The low vaccine effectiveness (41%) observed for H3 N2 in the 2012-2013 season was attributed to these three mutations during vaccine production 25.",
      "supports_claim": true,
      "explanation": "The quote appears in the document in the following passage: 'During the 2012-2013 northern hemisphere influenza vaccination campaign, HA from an egg adapted A/Victoria/361/2011 (H3 N2) virus used for vaccine manufacturing differed from the WHO-recommended prototype and several other wild type influenza viruses in three positions, H156 Q, G186 V, and S219 Y25. The low vaccine effectiveness (41%) observed for H3 N2 in the 2012-2013 season was attributed to these three mutations during vaccine production 25.' The wording and factual content are semantically equivalent to the quote to verify, with only minor differences in spacing and punctuation (e.g., 'H156 Q' vs 'H156Q'), which do not alter the meaning.. The quote directly supports the claim. It explicitly states that during the 2012-2013 influenza vaccination campaign, mutations (H156Q, G186V, S219Y) arose in the HA protein of an egg-adapted vaccine strain during production, and that these mutations were attributed to a reduction in vaccine effectiveness (41%). This provides a concrete example of how mutations developed during egg-based vaccine production can reduce vaccine effectiveness, which is exactly what the claim asserts.",
      "presence_explanation": "The quote appears in the document in the following passage: 'During the 2012-2013 northern hemisphere influenza vaccination campaign, HA from an egg adapted A/Victoria/361/2011 (H3 N2) virus used for vaccine manufacturing differed from the WHO-recommended prototype and several other wild type influenza viruses in three positions, H156 Q, G186 V, and S219 Y25. The low vaccine effectiveness (41%) observed for H3 N2 in the 2012-2013 season was attributed to these three mutations during vaccine production 25.' The wording and factual content are semantically equivalent to the quote to verify, with only minor differences in spacing and punctuation (e.g., 'H156 Q' vs 'H156Q'), which do not alter the meaning.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that during the 2012-2013 influenza vaccination campaign, mutations (H156Q, G186V, S219Y) arose in the HA protein of an egg-adapted vaccine strain during production, and that these mutations were attributed to a reduction in vaccine effectiveness (41%). This provides a concrete example of how mutations developed during egg-based vaccine production can reduce vaccine effectiveness, which is exactly what the claim asserts.",
      "original_relevance": "This quote links specific mutations that arose during egg-based vaccine production to a measurable reduction in vaccine effectiveness, directly supporting the claim."
    },
    {
      "id": 4,
      "quote": "Other antigenic mutations introduced by egg adaptation of the vaccine strain during vaccine manufacturing are thought to have contributed to low vaccine effectiveness estimates for H3 N2 in other influenza seasons 26 27.",
      "supports_claim": true,
      "explanation": "The quote appears on page 2 of the document, in the section discussing potential antigenic mismatch of influenza vaccine virus grown in egg or cells due to adaptive mutations. The text states: 'Other antigenic mutations introduced by egg adaptation of the vaccine strain during vaccine manufacturing are thought to have contributed to low vaccine effectiveness estimates for H3 N2 in other influenza seasons 26 27.' This matches the quote to verify, with only minor formatting differences (e.g., citation formatting), but the factual content and meaning are preserved.. The quote directly supports the claim. It explicitly states that antigenic mutations introduced by egg adaptation during vaccine manufacturing have contributed to low vaccine effectiveness in multiple influenza seasons. This affirms the claim that cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness. The quote is specific about the process (egg adaptation during manufacturing), the outcome (mutations), and the consequence (reduced effectiveness), thus providing direct support for the claim.",
      "presence_explanation": "The quote appears on page 2 of the document, in the section discussing potential antigenic mismatch of influenza vaccine virus grown in egg or cells due to adaptive mutations. The text states: 'Other antigenic mutations introduced by egg adaptation of the vaccine strain during vaccine manufacturing are thought to have contributed to low vaccine effectiveness estimates for H3 N2 in other influenza seasons 26 27.' This matches the quote to verify, with only minor formatting differences (e.g., citation formatting), but the factual content and meaning are preserved.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that antigenic mutations introduced by egg adaptation during vaccine manufacturing have contributed to low vaccine effectiveness in multiple influenza seasons. This affirms the claim that cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness. The quote is specific about the process (egg adaptation during manufacturing), the outcome (mutations), and the consequence (reduced effectiveness), thus providing direct support for the claim.",
      "original_relevance": "This quote generalizes the phenomenon, stating that mutations from egg adaptation during manufacturing have contributed to reduced effectiveness in multiple seasons, affirming the claim."
    },
    {
      "id": 5,
      "quote": "The use of recombinant protein technology eliminates the risk of antigenic mismatch due to potential changes in primary HA structure through egg- or cell adaptation.",
      "supports_claim": true,
      "explanation": "The quote appears on page 6 of the document: 'The use of recombinant protein technology eliminates the risk of antigenic mismatch due to potential changes in primary HA structure through egg- or cell adaptation.' The wording is nearly identical to the quote to verify, with only minor differences in punctuation and phrasing, but the factual content is preserved.. The quote directly supports the claim. It explicitly states that recombinant protein technology eliminates the risk of antigenic mismatch that can result from changes in the primary HA structure due to egg or cell adaptation. This directly affirms that cell- and egg-based flu vaccines have the potential to develop mutations during production (egg- or cell adaptation), which may reduce their effectiveness (antigenic mismatch).",
      "presence_explanation": "The quote appears on page 6 of the document: 'The use of recombinant protein technology eliminates the risk of antigenic mismatch due to potential changes in primary HA structure through egg- or cell adaptation.' The wording is nearly identical to the quote to verify, with only minor differences in punctuation and phrasing, but the factual content is preserved.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that recombinant protein technology eliminates the risk of antigenic mismatch that can result from changes in the primary HA structure due to egg or cell adaptation. This directly affirms that cell- and egg-based flu vaccines have the potential to develop mutations during production (egg- or cell adaptation), which may reduce their effectiveness (antigenic mismatch).",
      "original_relevance": "This quote supports the claim by stating that antigenic mismatch can result from changes in HA structure due to egg or cell adaptation, which recombinant technology avoids."
    },
    {
      "id": "comp_1",
      "quote": "The chances of introducing deleterious mutations through the adaptation of seed virus during vaccine manufacturing today are low due to the stringent quality control of the working seed virus. Indeed, as per current regulatory requirements, seed viruses must be confirmed for both genetic and antigenic match with their originating wild type virus before they can be used for vaccine production. Nonetheless, the time it takes to generate appropriate seeds could hinder the timely availability of the vaccines. Recombinant DNA technology avoids the risk of the virus acquiring egg- or cell adapted mutations during the manufacturing process as it does not use 'live' influenza virus.",
      "supports_claim": true,
      "explanation": "The quote appears on page 2 of the document, with only minor differences in formatting and wording. The factual content is preserved: 'The chances of introducing deleterious mutations through the adaptation of seed virus during vaccine manufacturing today are low due to the stringent quality control of the working seed virus. Indeed, as per current regulatory requirements, seed viruses must be confirmed for both genetic and antigenic match with their originating wild type virus before they can be used for vaccine production. Nonetheless, the time it takes to generate appropriate seeds could hinder the timely availability of the vaccines. Recombinant DNA technology avoids the risk of the virus acquiring egg- or cell adapted mutations during the manufacturing process as it does not use 'live' influenza virus.' This matches the quote to verify in all substantive details.. The quote directly addresses the claim. It states that there is a known risk of adaptive mutations occurring in cell- and egg-based vaccine production, which can reduce vaccine effectiveness. It further explains that while current quality control reduces this risk, it does not eliminate it, and that recombinant DNA technology avoids this risk entirely. Therefore, the quote explicitly supports the claim that cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
      "presence_explanation": "The quote appears on page 2 of the document, with only minor differences in formatting and wording. The factual content is preserved: 'The chances of introducing deleterious mutations through the adaptation of seed virus during vaccine manufacturing today are low due to the stringent quality control of the working seed virus. Indeed, as per current regulatory requirements, seed viruses must be confirmed for both genetic and antigenic match with their originating wild type virus before they can be used for vaccine production. Nonetheless, the time it takes to generate appropriate seeds could hinder the timely availability of the vaccines. Recombinant DNA technology avoids the risk of the virus acquiring egg- or cell adapted mutations during the manufacturing process as it does not use 'live' influenza virus.' This matches the quote to verify in all substantive details.",
      "support_explanation": "The quote directly addresses the claim. It states that there is a known risk of adaptive mutations occurring in cell- and egg-based vaccine production, which can reduce vaccine effectiveness. It further explains that while current quality control reduces this risk, it does not eliminate it, and that recombinant DNA technology avoids this risk entirely. Therefore, the quote explicitly supports the claim that cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
      "original_relevance": "This quote explicitly states that egg- or cell-based vaccine production carries a risk of acquiring adaptive mutations, which recombinant technology avoids, directly supporting the claim about mutation risk in traditional vaccine platforms."
    },
    {
      "id": "comp_2",
      "quote": "For the 2016-2017 season, the influenza vaccine was updated to include a clade 3 C.2 a H3 N2 strain (A/Colorado/15/2014) containing the new glycosylation site 26. However, this particular glycosylation site was absent in the egg adapted virus. Consequently, antibodies induced in humans, and in ferrets, poorly neutralised the glycosylated clade 3 C.2 a H3 N2 strain 26.",
      "supports_claim": true,
      "explanation": "The quote appears on page 2 of the document, with only minor differences in formatting and wording. The factual content is preserved: 'For the 2016-2017 season, the influenza vaccine was updated to include a clade 3 C.2 a H3 N2 strain (A/Colorado/15/2014) containing the new glycosylation site 26. However, this particular glycosylation site was absent in the egg adapted virus. Consequently, antibodies induced in humans, and in ferrets, poorly neutralised the glycosylated clade 3 C.2 a H3 N2 strain 26.' The document contains this passage almost verbatim.. The quote provides a specific example of a mutation (loss of a glycosylation site) occurring during egg adaptation in the production of the influenza vaccine. It further states that this mutation led to antibodies that poorly neutralized the circulating virus, directly supporting the claim that cell- and egg-based flu vaccines can develop mutations during production that may reduce their effectiveness.",
      "presence_explanation": "The quote appears on page 2 of the document, with only minor differences in formatting and wording. The factual content is preserved: 'For the 2016-2017 season, the influenza vaccine was updated to include a clade 3 C.2 a H3 N2 strain (A/Colorado/15/2014) containing the new glycosylation site 26. However, this particular glycosylation site was absent in the egg adapted virus. Consequently, antibodies induced in humans, and in ferrets, poorly neutralised the glycosylated clade 3 C.2 a H3 N2 strain 26.' The document contains this passage almost verbatim.",
      "support_explanation": "The quote provides a specific example of a mutation (loss of a glycosylation site) occurring during egg adaptation in the production of the influenza vaccine. It further states that this mutation led to antibodies that poorly neutralized the circulating virus, directly supporting the claim that cell- and egg-based flu vaccines can develop mutations during production that may reduce their effectiveness.",
      "original_relevance": "This quote provides a concrete example of a mutation (loss of a glycosylation site) occurring during egg adaptation, which led to reduced vaccine effectiveness, directly supporting the claim."
    },
    {
      "id": "comp_3",
      "quote": "t sst a (p 0 003. eest gato ssuggested tat a toug the circulating A/H3 N2 viruses were antigenic ally similar to the cell grown vaccine reference virus, egg propagation of the vaccine strains had led to loss of aglycosylation site and impaired antibody response to circulating viruses, consistent with previous reports 26.",
      "supports_claim": true,
      "explanation": "The quote appears on page 5 of the document, though with some OCR artifacts in the provided version. The relevant passage is: 'The investigators suggested that although the circulating A/H3 N2 viruses were antigenically similar to the cell grown vaccine reference virus, egg propagation of the vaccine strains had led to loss of aglycosylation site and impaired antibody response to circulating viruses, consistent with previous reports 26.' This matches the factual content of the quote to verify, including the mention of egg propagation leading to loss of a glycosylation site and impaired antibody response.. The quote directly supports the claim. It explicitly states that egg propagation of vaccine strains led to the loss of a glycosylation site and impaired antibody response to circulating viruses. This is direct evidence that mutations (specifically, loss of a glycosylation site) can occur during production in eggs and that these mutations can reduce vaccine effectiveness, which is exactly what the claim asserts.",
      "presence_explanation": "The quote appears on page 5 of the document, though with some OCR artifacts in the provided version. The relevant passage is: 'The investigators suggested that although the circulating A/H3 N2 viruses were antigenically similar to the cell grown vaccine reference virus, egg propagation of the vaccine strains had led to loss of aglycosylation site and impaired antibody response to circulating viruses, consistent with previous reports 26.' This matches the factual content of the quote to verify, including the mention of egg propagation leading to loss of a glycosylation site and impaired antibody response.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that egg propagation of vaccine strains led to the loss of a glycosylation site and impaired antibody response to circulating viruses. This is direct evidence that mutations (specifically, loss of a glycosylation site) can occur during production in eggs and that these mutations can reduce vaccine effectiveness, which is exactly what the claim asserts.",
      "original_relevance": "This quote describes how egg propagation led to the loss of a glycosylation site and impaired antibody response, providing direct evidence that mutations during production can reduce vaccine effectiveness."
    }
  ],
  "verification_stats": {
    "total_verified": 8
  },
  "image_evidence": []
}